By Denny Jacob

Drugmaker Merck & Co. and pharmaceutical company AstraZeneca PLC on Thursday said the Food and Drug Administration will extend the date for lynparza's pending supplement new drug application.

The companies said the extension is to provide more time to fully review the submission.

The application is for lynparza in combination with abiraterone and prednisone or prednisolone as a treatment for adults with metastatic castration-resistant prostate cancer, Merck and AstraZeneca said.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

December 15, 2022 07:15 ET (12:15 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Merck Charts.